For the third quarter of FY2026, revenue was JPY 127.135 billion (4.8% YoY increase) and operating income was JPY 32.333 billion (1.3% YoY decrease), leading to an upward revision of full-year revenue guidance by 1.2%.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4516","jir_company_name":"Nippon Shinyaku Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-02-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4516-20260209-01.pdf","jir_short_summary":"For the third quarter of FY2026, revenue was JPY 127.135 billion (4.8% YoY increase) and operating income was JPY 32.333 billion (1.3% YoY decrease), leading to an upward revision of full-year revenue guidance by 1.2%.","jir_summary":"### Performance Overview\nConsolidated Q3 revenue for FY2026 was JPY 127.135 billion, a 4.8% increase year-on-year. Despite price revisions and generic drug impacts in the pharmaceuticals segment, sales growth of 5.4% was supported by contributions from 'Uptravi,' 'Fintepla,' and the newly recognized product sales of 'Alliday.' The functional foods segment also increased by 1.1% due to higher sales of health food ingredients and supplements. Operating income declined by 1.3% year-on-year to JPY 32.333 billion due to increased SG&A expenses, and net income attributable to owners of the parent decreased 9.5% to JPY 25.844 billion.\n\n### Financial Position and Cash Flow\nTotal assets increased by JPY 44.47 billion from the previous consolidated fiscal year-end to JPY 328.108 billion, and total equity rose by JPY 36.856 billion to JPY 284.196 billion. Cash flow from operating activities generated inflows of JPY 12.002 billion, investing activities generated inflows of JPY 1.518 billion, and financing activities resulted in outflows of JPY 9.24 billion.\n\n### Revision of Consolidated Earnings Forecast\nThe full-year consolidated earnings outlook for FY2026 was revised upward based on changes in assumed exchange rates, revising revenue to JPY 170 billion (1.2% increase from previous forecast). There were no changes to the outlook for operating income, profit before tax, or net income attributable to owners of the parent.\n\n### Research and Development Status\nDevelopment is progressing domestically and internationally for multiple pharmaceuticals. Key focus products include Duchenne muscular dystrophy treatment 'Viltepso,' blastic plasmacytoid dendritic cell tumor treatment 'NS-401,' and epilepsy treatment 'Fintepla.' Efforts overseas include responses to FDA reviews and continuation of clinical trials.\n\n### Contingent Liability Litigation Status\nIn a U.S. patent lawsuit, the jury upheld Sarepta Therapeutics' patent validity. Nippon Shinyaku is considering an appeal and has not recorded any provision for damages.","jir_financial_highlights":"Revenue: JPY 127.135 billion (4.8% YoY increase)\nOperating Income: JPY 32.333 billion (1.3% YoY decrease)\nProfit before Tax for the Quarter: JPY 33.227 billion (0.6% YoY decrease)\nNet Income Attributable to Owners of Parent for the Quarter: JPY 25.844 billion (9.5% YoY decrease)\nTotal Assets: JPY 328.108 billion (Increase of JPY 44.47 billion from the previous consolidated fiscal year-end)\nTotal Equity: JPY 284.196 billion (Increase of JPY 36.856 billion from the previous consolidated fiscal year-end)\nNumber of Outstanding Shares (Including Treasury Stock): 70,251,484 shares (Same as previous fiscal year-end)\nNumber of Treasury Shares: 2,850,535 shares (Decrease from previous fiscal year-end)\nFull-Year Revenue Forecast: JPY 170.0 billion (1.2% increase from previous forecast)","jir_category":"","jir_hashtags":"#NipponShinyakuCoLtd, #FinancialSummary, #financial_summary, #JapaneseStocks","jir_key_figures":"Revenue: JPY 127.135 billion (4.8% YoY increase)\nOperating Income: JPY 32.333 billion (1.3% YoY decrease)\nNet Income Attributable to Owners of Parent for the Quarter: JPY 25.844 billion (9.5% YoY decrease)","jir_meta_title":"Nippon Shinyaku Co., Ltd. FY2026 Q3 Financial Summary - 4.8% Revenue Growth, 1.3% Decrease in Operating Income","jir_meta_description":"Nippon Shinyaku Co., Ltd. FY2026 Q3 Financial Summary. Revenue of JPY 127.135 billion (4.8% YoY increase), operating income of JPY 32.333 billion (1.3% YoY decrease). Full-year revenue forecast revised upward.","jir_og_title":"Nippon Shinyaku FY2026 Q3 Financial Results: 4.8% Revenue Increase, Slight Decrease in Operating Income","jir_og_description":"Nippon Shinyaku Co., Ltd. FY2026 Q3 Financial Summary. Revenue increased 4.8% YoY, operating income decreased by 1.3%.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend (in million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Cumulative Q3 FY2025\\\",\\\"Cumulative Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[121320,127135],\\\"borderColor\\\":\\\"#007bff\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend (in million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Cumulative Q3 FY2025\\\",\\\"Cumulative Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[32752,32333],\\\"borderColor\\\":\\\"#28a745\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"quarterly_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent for the Quarter Trend (in million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Cumulative Q3 FY2025\\\",\\\"Cumulative Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Quarterly Profit\\\",\\\"data\\\":[28552,25844],\\\"borderColor\\\":\\\"#dc3545\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue Breakdown (in million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceuticals Segment\\\",\\\"Functional Foods Segment\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Cumulative Q3 FY2025\\\",\\\"data\\\":[104560,16759],\\\"backgroundColor\\\":[\\\"#007bff\\\",\\\"#ffc107\\\"]},{\\\"label\\\":\\\"Cumulative Q3 FY2026\\\",\\\"data\\\":[110194,16941],\\\"backgroundColor\\\":[\\\"#0056b3\\\",\\\"#e0a800\\\"]}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"FY2026 Full-Year Revenue Forecast Comparison (in million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Previous Forecast\\\",\\\"Revised Forecast\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue Forecast\\\",\\\"data\\\":[168000,170000],\\\"backgroundColor\\\":[\\\"#6c757d\\\",\\\"#28a745\\\"]}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":false}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":7976,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-26040","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n